Malaysia Urges Support for Tobacco and Smoking Control Act

Aug.01.2022
Malaysia Urges Support for Tobacco and Smoking Control Act
Malaysia aims to curb addiction to cigarettes and e-cigarettes to prevent drug abuse and protect public health.

Kuala Lumpur: Addiction to cigarettes and e-cigarettes can pave the way for drug abuse habits, and it is important to curb drug abuse from the very beginning. Therefore, all parliamentary members are urged to support the 2022 Tobacco and Smoking Products Control Bill to ensure public health and protect people from the harmful effects of these products.


The Chairperson of the National Women, Family, and Fire Department is Datuk Jamilah Baba.


Datin Jamilah Bakar, the chairwoman of Malaysia's National Association for Drug Prevention (PEMADAM) and the Women, Family and Community Development Ministry, has stated that it is high time for the country to introduce specific legislation concerning tobacco products and smoking habits, rather than relying on the Food Act and Tobacco Products Control Regulations of 1983.


PEMADAM fully supports the 2022 Tobacco Products and Smoking Control Act, as well as the implementation of the Generasi End Smoking (GEG) provisions, which prohibit smoking and purchasing cigarettes, including electronic cigarettes, for individuals born after January 1, 2007. In a statement released today, PEMADAM stated, "We recognize that smoking and e-cigarette use are gateway behaviors to drug abuse. It is necessary to curb the habit of addiction to nicotine and related substances from the very beginning.


The Tobacco Products and Smoking Control Act of 2022 is a law that regulates the registration of tobacco products, smoking materials or tobacco alternatives. It also monitors advertising, promotion, sponsorship, sales, and purchases of tobacco products, smoking materials, tobacco alternatives, and smoking devices. The law emphasizes a ban on anyone born after 2007 from smoking any tobacco product or alternative, as well as banning the use of smoking devices.


Jamela further commented that the emergence of new smoking products such as electronic cigarettes has had a negative impact on health. She stated that this would continue to burden the country's healthcare system and further threaten the health of both smokers and non-smokers.


It is estimated that by 2030, the cost of treating inflammatory lung disease (EVALI) will reach RM369 million.


According to the 2016 Malaysian Adolescent Tobacco and E-cigarette Survey (TECMA) by the Public Health Institute, 330,000 individuals, or 15.2% of adolescents aged 13 to 17 (27.8% male and 2.6% female), are electronic cigarette (e-cigarette) users.


According to Jamella, the usage of adult e-cigarettes and e-cigarette users increased from 3.2% in 2016 to 4.9% in 2019. When calculated based on the total population, the number of e-cigarette users doubled in just three years, from 600,000 to 1.2 million people.


This article is a compilation of information from third-party sources, provided for educational and informative purposes only. The copyright for the compiled information belongs to the original media and authors. If any infringement is found, please contact us to remove the content.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
FDA Authorizes Four More Nicotine Pouches as Review Pilot Expands Beyond Initial Decisions
The FDA has authorized four additional on! nicotine pouches, bringing the U.S. total to 30. The decision marks another outcome of the agency’s nicotine pouch review pilot, whose communication and review practices are now being applied more broadly across the category. It also extends Helix’s authorized portfolio from on! PLUS to the earlier on! line. Yet all FDA-authorized nicotine pouches still come from subsidiaries of PMI or Altria, underscoring how concentrated U.S. regulatory access remains.
Aug.05
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
DOJO launched the BLAST10K Fresh in the UK on September 4, 2026, introducing its INSTA-JUICED™ technology and a new 0+10ml structure that keeps e-liquid separated from the coil before activation. The device features a 1000mAh rechargeable battery, COREX BLAST dual-mesh technology and SSS leak-resistant technology, with a manufacturer-rated capacity of up to 10,000 puffs. It also retains compatibility with existing 2+8ml pods across the BLAST ecosystem. The launch introduces eight new flavors, including Matcha Strawberry, which DOJO describes as an industry first.
Market
Sep.04
Imperial Brands Plans Thousands of Job Cuts Across U.S. and Europe in Cost Restructuring
Imperial Brands Plans Thousands of Job Cuts Across U.S. and Europe in Cost Restructuring
According to Reuters, citing Bloomberg News, British tobacco company Imperial Brands PLC plans to cut thousands of jobs across the United States and Europe as part of a cost reduction and organizational restructuring effort. The announcement drew market attention to the company’s shares. The move comes as global tobacco companies continue adjusting their operations amid slower cigarette market growth, changing consumer preferences and the transition toward next-generation nicotine products.
Aug.11
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Bets on Age-Gating and 678 PMTA Assets as U.S. Vape Enforcement Landscape Shifts
Charlie’s Holdings said in its latest shareholder letter that it is moving to commercialize PACHA products and monetize its PMTA assets as the FDA changes enforcement priorities for unauthorized ENDS products. Thirty PACHA SKUs were previously tentatively identified for a proposed public list of products that the FDA generally does not intend to prioritize for enforcement. Charlie’s is also preparing test-market sales of age-gated flavored disposables and says it currently holds 678 PMTA-related product assets while seeking additional strategic transactions and partnerships.
Sep.11
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Says 30 PACHA Vape SKUs Tentatively Identified for FDA’s Non-Priority Enforcement Public List
Charlie’s Holdings said the U.S. Food and Drug Administration notified the company on June 23, 2026, that 30 PACHA vape SKUs with submitted PMTAs had been tentatively identified for inclusion on a planned public-facing FDA webpage. Under enforcement guidance issued by FDA in May, the webpage is intended to identify certain unauthorized products for which the agency generally does not intend to prioritize enforcement of premarket authorization requirements. Charlie’s disclosed the development alongside second-quarter revenue of $3.8 million, up 116% year over year.
Aug.25